
33-year-old-male-patient:
-
- Presented with jaundice
- laboratory tests revealed elevated levels of serum alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, and direct bilirubin
What do you see?
-
- A lobulated mass within the bile ducts (shown in red areas)
- Dilatation of intrahepatic bile ducts
-
- A 3.5-cm-lobulated mass within the bile ducts (red arrows) with
upstream and downstream dilatation of bile ducts
What is your diagnosis?
-
- Intraductal papillary neoplasm of the bile duct (IPNB) with invasive carcinoma
- In our case, the patient underwent surgery and the diagnosis was histopathologically confirmed
Teaching points
-
- IPNBs are premalignant biliary epithelial tumors.
- IPNBs originate from and communicate with the biliary tree and can occur anywhere along the biliary tree.
- 30-40% of IPNBs exhibit mucin hypersecretion.
- When symptomatic, patients present with recurrent abdominal pain, cholangitis, and jaundice.
- Risk factors for IPNBs include hepatolithiasis, clonorchiasis, primary sclerosing cholangitis, biliary tree malformations, choledochal cysts, and familial adenomatous polyposis.
- IPNB is analogous to the intraductal papillary mucinous neoplasm of the pancreas (IPMN).
- Imaging findings of IPNB include:
-
- Intraductal mass with upstream and downstream dilatation
- Complex cystic mass with biliary ductal dilatation
- Ductal dilatation without a mass, with associated parenchymal atrophy
- Thread sign at MRCP (linear and curved filling defects due to mucin)
- IPNBs may be associated with invasive carcinoma (27-94%)
- Imaging findings that suggest invasive carcinoma at MRI include
-
- A visible intraductal mass
- Tumor size greater than 2.5 cm
- Tumor multiplicity
- Ductal wall thickening
- Adjacent hepatic invasion
- Early surgical intervention is the key management for IPNB.
- All patients with IPNB should be considered for treatment, given the high potential for malignancy and for recurrent cholangitis and obstructive jaundice in nonmalignant cases
Published by EDiR Holders
Second generation of EDiR Holders
View all posts by EDiR Holders
Klatskin tumor